This research service considers products and companies in the obesity surgery devices market in the United States. The market is expected to see many technology advancements in the next decade. Therefore, a thorough understanding of revenue forecasts, unit forecasts, technological advances, and pricing analyses are provided for the market's various segments including: gastric banding, gastric stimulators, and intragastric balloons. Furthermore, market engineering measurements, drivers, and restraints are covered along with an analysis of the market's highly competitive landscape. The base year is 2011; the forecast period extends through 2016.
Total revenue generated by sales of obesity surgery devices in the United States in 2011 was approximately $x million, representing a x percent increase over 2010.
Revenue in the U.S. obesity surgery devices market is projected to grow at a compound annual growth rate (CAGR) of x percent from 2011 to 2016, reaching $x million in 2016.
In 2011, only gastric banding was approved in the United States. Going forward, newer technologies such as intragastric balloons and gastric stimulators are expected to be launched.
The company generating the highest revenue in the U.S. therapeutic surfaces market in 2011 was Allergan. The other company in this space is Ethicon Endo-Surgery.
Rising obesity and increasing published literature on the risks of obesity are the main contributors to the overall market growth. Also, comorbidities associated with obesity such as diabetes and cardiovascular diseases are on the rise.
Click for Report details:Analysis of the U.S. Obesity Surgery Devices Market